A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

MedStar Georgetown University Hospital: Patients Can Now Benefit from Same-day Procedure to Diagnose and Treat Lung Cancer

Georgetown University Hospital: Imagine being diagnosed with lung cancer and having the tumor surgically removed on the same day, thereby increasing the opportunity for limited follow-up therapy – or even curing the cancer.

A team of pulmonary and thoracic experts at MedStar Georgetown University Hospital are the first in the region to combine these two steps, thus saving precious time for patients in addressing the “beast of all cancers,” according to Eric D. Anderson, MD, director of Interventional Pulmonology at MedStar Georgetown University Hospital.

“Coupling this early diagnosis with same-day surgery for lung cancer is a win for patients,” said Dr. Anderson. “Given the impact of lung cancer – the leading cause of cancer deaths — this is a major step towards stopping the disease in its tracks, resulting in better outcomes and giving patients an improved chance at life.”

In this new approach – Combined Robotic Assisted Thoracic Surgery (CRATS) – high-risk lung cancer patients first undergo a low dose CT scan of the lung to monitor for tumors. If a tumor is detected, the Ion robot bronchoscope is used to biopsy the lung tumor. If the lung tumor is found – through real-time biopsy – to be cancer, then the endobronchial ultrasound is used to determine if the cancer has spread to lymph nodes. If the lymph nodes are normal, then the patient undergoes surgery to remove the portion of the lung with the cancerous tumor using the DaVinci robotic video-assisted thoracic surgery system during the same anesthesia procedure. This new process – diagnosing lung cancer and removing the tumor at the same time — saves valuable time by removing the cancer right when it is detected, thereby limiting the opportunity for spread of disease and allowing for the start of additional therapies sooner if needed. In some instances, this approach can be curative of the cancer.

“Millimeters matter,” says Dr. Anderson. “We know that the earlier we find the nodule in the lung and the smaller it is, that has the greatest impact on mortality. If we find the nodule at 1 mm, there is 90% chance of survival. At 2 mm, there is 80%, and at 3 mm 70%. Combine those odds with the potential immediate removal of the tumor, and the Ion robot gives patients a real chance for better outcomes.”

Previously this process of diagnosis and treatment could take several weeks — a critical time when cancer can continue to grow, and patients can experience increased anxiety about their health and prognosis.

“This combined therapy of diagnosis and surgical removal of the tumor at the same time offers new hope for patients with lung cancer,” said Dr. Marc Margolis, Chief of Robotic Thoracic Surgery at Medstar Georgetown University Hospital, “Removing a cancerous tumor in the lung, when possible, is key to advancing the opportunity for improved outcomes for these patients. The earlier we can remove the cancer, the sooner we can help our patients with any additional therapies they may need to move forward with their life.”

Wayne Norris, 67, had the low dose CT lung screen that indicated a tumor. He was immediately scheduled for the combined procedure in the event the tumor was cancer.

“We feel blessed not to have had to wait for biopsy and to schedule surgery. It was a relief to get this all taken care of at one time and get the cancer out,” said Norris, whose tumor was diagnosed as cancer and removed immediately.


Ion Robot: MedStar Georgetown University Hospital is the first and only hospital in the region to have the Ion robot — a “game-changing” tool according to Dr. Anderson, that enables surgeons to reach peripheral nodules in the lung to diagnose lung cancer sooner, thereby increasing the opportunity for earlier diagnosis and treatment of lung cancer, the leading cause of cancer deaths worldwide for both men and women.

Ion endoluminal is a minimally invasive robotic-assisted system that helps address a challenging aspect of lung biopsy by enabling physicians to obtain tissue samples from deep within the lung.

While survival rates for lung cancer have improved over the past decade in part due to early screening, physicians know that improved outcomes are directly linked to early detection. Coupled with regular screening for those at high risk, the Ion system makes possible earlier and more accurate detection of cancer, especially for small nodules.

In addition to giving surgeons real-time guidance for improved accuracy, the Ion robot can navigate through small and tortuous airways to reach nodules in any airway segment within the lung with its flexible biopsy needle that can pass through very tight bends to collect tissue in the peripheral lung. The catheter’s 2 mm working channel can also accommodate other biopsy tools, such as biopsy forceps and cytology brushes, if necessary. The system’s fiber-optic shape sensor technology, developed by Intuitive, is to provide the physician with the precise location and shape information of the catheter throughout the navigation and biopsy process.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy